Authors Posts by Head Editor

Head Editor

5007 POSTS 18 COMMENTS

0 1211

Rocky Mountain High Brands Discusses Series A Preferred Restructuring

DALLAS, March 17, 2017 (GLOBE NEWSWIRE) — Rocky Mountain High Brands, Inc. (RMHB), a fully reporting consumer goods company specializing in hemp-infused food and beverage products and a naturally high alkaline water, offered an explanation of its recent move to increase the voting and conversion rights of its Series A Preferred Stock.

Michael Welch, President and Chief Executive Officer of Rocky Mountain High Brands, Inc., said, “With the recent acquisition by LSW Holdings, LLC of the Company’s Series A Preferred Stock, we have reviewed our equity structure and are making changes to it to both protect the Company and to provide for its future growth. The Series A Preferred Stock is the Control Block for the Company. It has special rights associated with it and is not designed or intended to be converted to Common Stock. Changes to its voting rights and conversion rights were made to ensure that LSW Holdings maintains control of the Company in the event of corporate actions such as a merger/acquisition or hostile takeover.”

Welch continued, “Lily Li and other principals and representatives of LSW Holdings were in Dallas this week to meet our Rocky Mountain High team and discuss future plans for the Company. With the opportunities that LSW Holdings will bring into the Company, we need to protect the Company and its shareholders from a hostile takeover or any other uninvited action not in the best interest of the Company or its shareholders. The restructuring of the Series A Preferred Stock voting and conversion rights are a part of that plan.”

About Rocky Mountain High Brands:

ROCKY MOUNTAIN HIGH BRANDS, INC., is a consumer goods company specializing in brand development of health conscious, hemp-infused food and beverage products. The Company currently markets a lineup of four naturally flavored hemp-infused beverages (Citrus Energy, Black Tea, Mango Energy and Lemonade) and a low calorie Coconut Lime Energy drink. Rocky Mountain High Brands also offers hemp-infused 2oz. Mango Energy Shots and Mixed Berry Energy Shots. The Company recently launched a naturally high alkaline spring water, Eagle Spirit Spring Water.

For interested investors, our stock symbol is RMHB.

For ordering information please visit: LiveRockyMountainHigh.com

For corporate information please visit: RockyMountainHighBrands.com

For information on our high alkaline water visit: EagleSpiritWater.com

For Rocky Mountain High Distribution Contact:

Chuck Smith (972) 955-0964
chuck@rockymountainhighbrands.com

Visit us on Facebook: https://www.facebook.com/rockymountainhighbrands?fref=nf

Visit us on Twitter:
#GetYourHempOn

Visit us at Investors Hangout: http://investorshangout.com/Rocky-Mountain-High-Brands-Inc-RMHB-69150/

Investors Hangout is the only authorized Investors blog page for Rocky Mountain High Brands, Inc.

Safe Harbor Act: This release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

0 2055
marijuana_glaucoma

Research has shown that cannabinoids can alleviate glaucoma-related symptoms because they lower the intraocular pressure (IOP) and have neuroprotective actions. For example, in 1971, one of the first studies of its kind found ingestion of cannabis lowers IOP by 25 to 30%. Despite the findings from early research, very few ophthalmologists support the use of medical cannabis in patients with early to mid-stage glaucoma. The main issue ophthalmologists have with marijuana is that the potential adverse effects, particularly smoking cannabis, outweigh the short term benefits. For example, smoking can lead to unstable intraocular pressure, which heightens the risk of permanent vision loss.

Additionally, because its therapeutic effects on glaucoma are short-term, patients would have to consume marijuana frequently; once every three to four hours. Physicians claim that because glaucoma needs to be treated 24 hours per day, patients would need to consume marijuana six to eight times over the course of a day to achieve consistently decreased IOP levels. Such frequency is difficult to maintain and could heighten the risk of developing a marijuana use disorder. However, when it comes to late stage glaucoma, ophthalmologists are more inclined to embrace cannabis as a treatment. At the end stages of glaucoma, it is less about directly targeting the glaucoma and more about alleviating the accompanying symptoms.

Ophthalmologist Andrew Bainnson, MD stated, “We’ve known for some time that medical marijuana is very effective for treating nausea and pain, but not so much for glaucoma. However, there are some patients with end stage pain and nausea who may benefit [from medical marijuana], but not from the glaucoma point of view.” The body’s own internal cannabinoid system, called the endocannabinoid system (ECS), is one of our most important physiological systems. Nearly every aspect of our health including: inflammation, immune response, neuroprotection, pain modulation, are all dependent on the ECS. Given the vital role of the ECS, particularly in neuroprotection and inflammation, many scientists believe the development of cannabinoid-based medications may be useful in treating glaucoma.

0 1090

PharmaCyte Biotech CEO Addresses IND Submission Questions

LAGUNA HILLS, Calif., March 17, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today released a statement by Chief Executive Officer Kenneth L. Waggoner that addresses the company’s position on releasing a date for filing its Investigational New Drug application (IND). Mr. Waggoner’s statement can be read below:

PharmaCyte does not plan to publish a date for the filing of its IND. At the current time, it’s extremely difficult for the company to supply a development timeline that will accurately predict when the IND will be filed. It would be irresponsible of the company to release what, at this point, would be a “hopeful” date for filing the IND. This date could change from day-to-day and week-to-week based upon several unforeseen variables – many of which are beyond PharmaCyte’s control. This means that we cannot give an accurate timeline for filing the IND because we too are awaiting a list of items to be completed by others.

What can be said with certainty is that PharmaCyte is on the right track for filing its IND at the earliest opportunity. With the help of Facet Life Sciences and TD2, the company is committed to doing everything the right way by following the guidance given to the company by the FDA during the pre-IND meeting. In doing that, PharmaCyte will maximize the possibility of preparing a successful IND rather than having the company’s IND put on clinical hold or even outright denied because it didn’t follow the FDA’s guidance. Getting to a point where the IND can be filed is not an overnight or even a one-month process. During the company’s conference call, I tried to convey this point to shareholders. Any shareholder who thought that the pre-IND meeting would be held one day and then the IND would be filed the next had completely unrealistic expectations. This never occurs.

PharmaCyte’s pre-IND meeting with the FDA was the best possible way for the company to introduce its pancreatic cancer therapy, past clinical trial results and trial design to the FDA, and, in turn, received invaluable feedback from the FDA and suggestions and ideas to best advance our therapy in the clinical trial. The pre-IND meeting served as the starting point of getting PharmaCyte and the FDA on the same page for the company to properly prepare for a clinical trial in inoperable locally advanced pancreatic cancer (LAPC).

The pre-IND meeting represented a critical point in the regulatory process for PharmaCyte and allowed the company to establish a strong relationship with the FDA. It also provided PharmaCyte and the FDA the opportunity to agree on a development strategy that should lead to a successful IND and, hence, the start of the clinical trial. The discussions held during the pre-IND meeting have the potential to save PharmaCyte both time and money in the long run, and have definitively shaped the overall strategy for the development of PharmaCyte’s therapy for LAPC.

If you’re wondering how the pre-IND meeting could have meaningfully benefited PharmaCyte and possibly reduce time to market, the FDA has addressed this question on its website, indicating the following benefits pertaining to PharmaCyte:

Identifying and avoiding unnecessary studies;

Ensuring that necessary studies are designed to provide useful information to the FDA;
Gaining FDA support for PharmaCyte’s proposed strategy;

Minimizing the chance for a clinical hold being issued by the FDA after filing the IND which would, of course, delay the start of the clinical trial;

Providing an opportunity for PharmaCyte and the FDA to creatively embark upon an exchange of ideas about all aspects of the clinical trial;

Obtaining regulatory insight from the FDA into the proposed clinical trial, particularly about PharmaCyte’s cell therapy for LAPC;

Minimizing costs so PharmaCyte doesn’t unnecessarily spend money on its development program;

Defining acceptable endpoints and goals that the FDA finds acceptable; and

Allowing early interactions and ongoing negotiations with the FDA related to the clinical trial.
The company now has the guidance it needs to complete what is expected to be a successful IND process. PharmaCyte was charged with completing numerous tasks identified by the FDA during the pre-IND meeting. Many of these tasks came about because PharmaCyte’s treatment for LAPC is novel in that it is a live cell-based therapy that also involves a unique form of cell encapsulation technology. When these tasks are completed by PharmaCyte, Austrianova, TD2 and others, PharmaCyte will file its IND. It will be then that the public is notified the IND has been filed.

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.

In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.

Safe Harbor

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements because of the impact of a number of risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.

0 1031

Medical Marijuana, Inc.’s CBD Oil RSHO-X™ Garners National News Headlines Across Mexico For Significantly Reducing Seizures Of Epileptic Children

SAN DIEGO, March 17, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its subsidiary HempMeds® Mexico garnered national news headlines across Mexico for the positive results of a recent study conducted by renowned Mexican physician Dr. Saul Garza Morales on the effects of its RSHO-X™ product in treating children with severe epilepsy. HempMeds® Mexico was the first company to receive government import permits for its cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X™) via the Mexican Health Department COFEPRIS.

An article from Mexico newspaper Reforma, “Ayuda cannabidiol a 84% de pacientes,” or “Cannabidiol helps 84% of patients,” explained how 84 percent of children with epilepsy treated with RSHO-X™ halved the number of seizures they suffer from, according to this first clinical study on the use of cannabis in patients with Lennox-Gastaut syndrome in Mexico.

“We are proud that our cannabidiol (CBD) hemp oil product, without THC, has enabled 17% of patients in the study to experience 100 percent relief from their seizures, the best results of any product/medication in the world regarding the reduction of seizures in Lennox-Gastaut patients,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It is exciting to see such widespread news coverage of these study results by the Mexico media, as studies that prove the therapeutic benefits of CBD like Dr. Garza’s study will continue to help fuel less restrictive medical cannabis programs not only in Mexico, but across the globe. In addition, as news spreads of this revolutionary treatment for diseases such as epilepsy, more patients and families that suffer from debilitating medical conditions will receive help with medical marijuana.”

The study included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of 4. Of those 39 patients, who took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced a 50% or greater reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and seven reported a complete elimination of all seizures (17%) over a four-month period, with zero reported side effects.

Results of this study are set to be published in the near future. To view the study, click here.

Other major national Mexico outlets that have reported the results of Dr. Garza’s epilepsy study with RSHO-X™ include:

Contenido

Economiahoy.mx

El Diario.mx

El Imparcial

El Mural

El Universal

Frontera.info

La Cronica

La Jornada

Radio Centro

Yahoo Mexico

Zocalo

About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

CONTACT:
Public Relations Contact: Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829- 0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

1 2636

Cannabis shops and manufacturers have increasing concerns that the Trump Administration will enforce federal laws that restrict farming and selling the drug. This will reverse the president’s stance during his campaign and potentially overturn what has become a $7 billion industry. The worry was provoked by comments from White House spokesman Sean Spicer recently that the government would most likely boost its enforcement of drug laws.

Attorney General Jeff Sessions stated that he is “dubious” about the benefits of marijuana. He said, “Marijuana is against federal law, and that applies in states where they may have repealed their own anti-marijuana laws. So yes, we will enforce law in an appropriate way nationwide. It’s not possible for the federal government, of course, to take over everything the local police used to do in a state that’s legalized it. And I’m not in favor of legalization of marijuana. I think it’s a more dangerous drug than a lot of people realize.”

The comments have sparked worry with Chuck Smith, co-founder of Dixie Brands, a Denver-based company that manufactures topicals and edibles infused with THC, the active ingredient in cannabis. He founded the company in 2010 and now employs more than 100 people across Arizona, Colorado, California, and Nevada. Smith stated, “My concern right now for both the company and industry is just uncertainty. It’s hard to build an industry or a company when you don’t have clarity.”

The administration’s statements affected shares of Innovative Industrial Properties, which invests in cannabis-growing facilities and is one of the few publicly traded cannabis companies. Its stock price plummeted on the day of Spicer’s press conference and are down more than 13% since then. However, two other marijuana stocks, GW Pharmaceuticals and Cara Therapeutics, seem to have not been affected by the news.

Eight states now allow the use of cannabis recreationally, while more than two dozen states have legalized it for medical purposes. Twenty-one states have decriminalized cannabis. A recent Quinnipiac Poll found 71% of voters think the government should not restrict federal drug laws in states where marijuana is legal. Increasing acceptance has led to an jump in the market for cannabis in North America, with sales rising 34% to nearly $7 billion in 2016, according to Arcview Market Research. By 2021, the industry is likely to climb close to $22 billion.

Companies like Dixie Brands are charging that hike. The privately held company would not disclose current numbers, but in 2014 it was valued at $40 million. Smith said, “It’s hard for us to kind of go backwards. President Trump said he was going to allow this to be a state’s rights issue. We took him at his word.” Trump has sent mixed messages on cannabis. In the 1990s, he called for legalizing all drugs. On the campaign trail, he reiterated his support for medical cannabis and his deference to states to pass their own laws regulating the drug.

2 1749

The cannabis industry continues to face threats from Attorney General Jeff Sessions as his campaign against cannabis continued this week.

The AG recently said, “I realize this may be an unfashionable belief in a time of growing tolerance of drug use. But too many lives are at stake to worry about being fashionable. I reject the idea that America will be a better place if marijuana is sold in every corner store. And I am astonished to hear people suggest that we can solve our heroin crisis by legalizing marijuana – so people can trade one life-wrecking dependency for another that’s only slightly less awful. Our nation needs to say clearly once again that using drugs will destroy your life.”

Sessions should take a lesson from Joe Rogan. In a YouTube video, Rogan said, “The only reason why marijuana is illegal is because of economics. If marijuana was legal, it would cost pharmaceutical and alcohol companies billions of dollars every year. The Partnership for a Drug-Free America is funded by alcohol companies. Alcohol is a sanctioned drug”

Marijuana can treat several debilitating diseases and improve the daily life of millions of people around the world.

Ten illnesses that can be treated by marijuana

1.Marijuana can be used to treat and prevent glaucoma. According to the National Eye Institute, marijuana decreases the pressure inside the eye. “Studies in the early 1970s showed that marijuana, when smoked, lowered intraocular pressure (IOP) in people with normal pressure and those with glaucoma.”

2.Marijuana helps reverse the carcinogenic effects of tobacco and improves lung health. In January 2012, a study was published in Journal of the American Medical Association which said marijuana does not impair lung function and it can even increase lung capacity.

3.Marijuana can help control epileptic seizures. Charlotte Figi suffers from Dravet’s Syndrome and a strain of marijuana called “Charlotte’s Web” has decreased Charlotte’s seizures from 300 a week to just one every seven days.

4.Marijuana can decrease anxiety. In 2010, researchers at Harvard Medical School suggested that that some of marijuana’s benefits may be associated with reduced anxiety.

5.THC slows the progression of Alzheimer’s disease. A study led by Kim Janda of the Scripps Research Institute suggests that marijuana may be able to slow the progression of Alzheimer’s disease. In 2006, the study published in the journal of Molecular Pharmaceutics found that THC, the active chemical in marijuana, slows the formation of amyloid plaques by blocking the enzyme in the brain that makes them. These plaques are what kill brain cells and cause Alzheimer’s.

6.Marijuana helps ease the pain associated with multiple sclerosis. GW Pharmaceuticals (GWPH) has developed a drug derived from cannabis called Sativex which helps patients who suffer from multiple sclerosis.

7. Marijuana relieves arthritis discomfort. In 2011, researchers said that marijuana alleviates pain, reduces inflammation and promotes sleep, which may help relieve pain for people suffering from rheumatoid arthritis.

8.Marijuana can potentially eliminate Crohn’s disease. A study in Israel showed that smoking a joint significantly reduced Crohn’s disease symptoms in 10 out of 11 patients. Marijuana caused a complete remission in five of the patients.

9.Marijuana helps veterans suffering from PTSD. The Department of Health and Human Services recently signed off on a proposal to study marijuana’s potential as part of the treatment for veterans with post-traumatic stress disorder.

10.Marijuana reduces some of the pain and nausea from chemotherapy and stimulates appetite.

0 1561

$VPRB Brands will be participating in the upcoming ASD Market Week Show

VPR Brands, LP (OTC PINK: VPRB) is looking forward to attending the ASD market week trade show starting on Sunday March 19 and ending Wednesday March 22, 2017 in booth # SL3564 at the Las Vegas Convention Center. VPR Brands will be featuring its HELIUM Brand eliquid www.vapehelium.com and its HONEY STICK Brand Vaporizer line www.vapehoneystick.com as well as its new all in one smoke kit the ALPHA-PUFF www.alphapuff.com and the KUSH ARMY KNIFE the must have multi tool gadget for smokers www.kusharmyknife.com.


Click Here Now To Read Full PR


$VNNYF Develops a Disruptive Solvent Based Extraction System

 

Vinergy Resources Ltd. (“Vinergy” or the “Company”) (CSE:VIN) (OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce it has developed a disruptive solvent based extraction system. The project currently underway for an existing customer, utilizes an ethanol / CO2 co-solvent blend and specialized equipment to achieve medicinal products with significantly increased purity. The current iteration of the machine has the physical footprint of a standard shipping skid and incorporates safety and process control systems in one easy to use platform.


Click Here Now To Read Full PR


$IMLFF Announces Publication of Discussion on the R&D of Cannabinoids

 


NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals ( CSE : IN ) ( OTCQB : IMLFF ), an NNW client that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

The publication, entitled, “Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth,” discusses the rampant growth of the cannabis market and how a number of biotech companies are developing cannabinoid-based therapies to address unmet medical needs.

 


Click Here Now To Read Full PR


Can CBD Yield A Positive Result On A Drug Test?


CBD is well-known for its health benefits, especially in treating rare seizure disorders. There are other reasons people try CBD products, also. A neurologist and psychopharmacology researcher, Dr. Ethan Russo, notes in a study that the therapeutic effects of CBD are broad, including: analgesic, anti-inflammatory, antiemetic, antioxidant, anti-psychotic, anti-anxiety, anti-convulsant and cytotoxic in certain cancer cells. Typically, CBD products are primarily made from the concentrated extract of the flowers, leaves and possibly stalks of marijuana or hemp. Most CBD products are either oil-based tinctures or capsules that are consumed orally, or topicals applied to the skin. However, there is a growing variety of other products containing CBD, including those for pets.

 


Click Here Now To Read Full Article


 

 

Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and Vinergy Resources, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1223

VPR Brands will be participating in the upcoming ASD Market Week Show in Las Vegas

VPR Brands, LP (OTC PINK: VPRB) is looking forward to attending the ASD market week trade show starting on Sunday March 19 and ending Wednesday March 22, 2017 in booth # SL3564 at the Las Vegas Convention Center. VPR Brands will be featuring its HELIUM Brand eliquid www.vapehelium.com and its HONEY STICK Brand Vaporizer line www.vapehoneystick.com as well as its new all in one smoke kit the ALPHA-PUFF www.alphapuff.com and the KUSH ARMY KNIFE the must have multi tool gadget for smokers www.kusharmyknife.com.

“The ASD trade show allows us to see a great cross section of our customer base from distributors to major retailers as well as gift, novelty, smoke and alternative shops all in one venue. What’s great about this show it is one of the most well attended trade shows of the year and it seems most stores while they may miss some of the other shows they make sure not to miss the ASD show. We will be showcasing all of our brands and products at this show from convenience store product to smoke shop and vape shop product in the newly designated Culture+ section of the show featuring all the major national branded glass, smoke, vape and accessories from around the country and internationally,” says Kevin Frija CEO of VPR Brands.

Dawn Kershaw, National Sales Manager of VPR Brands says, “I love to do business in Las Vegas, we work around the clock and still get a chance to socialize and get to know all our best customers outside of the show floor and see them year after year it’s almost like a family reunion and more importantly ASD is one of the best order writing shows since it is rather late in the trade show season most of the customers will actually take the time to write order on the spot, there is nothing better!”

WHAT IS ASD MARKET WEEK?
ASD Market Week is the most comprehensive B2B trade show that brings the world’s widest variety of retail merchandise together in one efficient shopping experience. 45,000 buyers from 88 countries visit ASD Market Week each year. From department stores to convenience stores, general stores to gift shops, from grocery store distributors to fashion boutiques, this is the trade show where any buyer can find unique merchandise that will set their store merchandise apart. Over 45,000 people attend ASD Market Week. Of those, 98% of our attendees have purchasing major purchasing power. The average buyer spends $82,500 per show, equating to $2.8 billion annually across hundreds of product categories. 88% of our buyers are domestic and 12% are international. The countries with biggest international presence are Mexico and Canada.

About VPR Brands, LP:
VPR Brands is a technology company, whose assets include issued U.S. and Chinese patents for atomization related products including technology for medical marijuana vaporizers and electronic cigarette products and components. The company is also engaged in product development for the vapor or vaping market, including e-liquids, vaporizers and electronic cigarettes (also known as e-cigarettes) which are devices which deliver nicotine and or cannabis through atomization or vaping, and without smoke and other chemical constituents typically found in traditional products. For more information about VPR Brands, please visit the company on the web at www.vprbrands.com.

Forward-looking statements:
This news release contains statements that involve expectations, plans or intentions, and other factors discussed from time to time in the company’s Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. The company cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contact Information:
VPR Brands, LP
Kevin Frija, CEO
(954) 715-7001
info@vprbrands.com

0 1307

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use

The publication, entitled, “Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth,” discusses the rampant growth of the cannabis market and how a number of biotech companies are developing cannabinoid-based therapies to address unmet medical needs.

To view the full publication visit: https://www.networknewswire.com/biotech-innovations-drive-cannabinoid-based-pharmaceutical-market-growth/

“Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc.’s (IMLFF) flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). As of now, there is no cure for EB. INM-750 is the first treatment ever developed specifically for this disease that has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and possibly reverse the course of the disease through the modulating of keratins in the skin. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects.”

InMed’s pipeline is further discussed in the publication, alongside a look at several industry peers.

About InMed

InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary bioinformatics database assessment tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company.

For more information, visit www.inmedpharma.com

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and contributing writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://nnw.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

0 2233

According to a story that appeared a couple of years back in The Philadelphia Inquirer, law enforcement in Pennsylvania were arresting about 21,000 people each year for possession of cannabis, and another 5,500 for growing marijuana. The column by Chris Goldstein, an editor at Freedom Leaf magazine, cited a report from the RAND Corp. think tank that estimated it costs $1,266 for the handling of every basic misdemeanor marijuana arrest.

That number rises to $8,600 for each prosecution of someone accused of growing the plant. Based on those figures, it predicted that Pennsylvania was spending more than $73 million a year on those cases, and that doesn’t include the costs of jail, prison, and supervision of those sentenced to parole and probation. What if Pennsylvania could not only wipe out those costs, but also gain millions from cannabis?

State Auditor General Eugene DePasquale said the state could earn $200 million a year by permitting recreational cannabis use and taxing it. At a recent news conference the auditor general noted that Colorado, with less than half the population of our state, is pulling in about $129 million annually through taxes on the farming and purchase of cannabis. In Washington state, that figure is $220 million.

DePasquale isn’t foolish enough to think such a move would find easy sledding in our Legislature, which has never had a reputation for being particularly visionary — or productive, for that matter. “It is an entirely fair and appropriate question to say, can this ever happen in Pennsylvania?” he said. In fact, it took years of pleas and protests from advocates before the Legislature finally approved use of medical marijuana in 2016, and that option won’t even be available to those who need it until next year, if all goes well.

House Republican spokesman Steve Miskin stated, “We don’t even have the medical cannabis program up and running yet, so it’s clearly a little premature to jump to the next step. While we’re appreciative of the auditor general’s multiple policy thoughts, as Pennsylvania and the nation is facing a serious drug problem, I’m not sure that legalizing a Schedule I narcotic is the best response.”

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements